紐約一線醫生：COVID-19 clinical update with Dr. Daniel Griffin

December 11, 2021

In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.

 

 

 

Links for this episode

• Risk associated with Omicron (medRxiv) 2:00
• Expansion of monoclonal EUA (FDA) 6:32
• Neutralization of Omicron by sera (medRxiv) 11:42
• Third dose sera neutralize Omicron (Pfizer) 15:13
• Monoclonals authorized for PreP (FDA) 18:30
• Patient outcomes after monoclonals (Open Forum Inf Dis) 22:33
• Subcutaneous or intramuscular monoclonals (medRxiv) 23:38
• WHO does not recommend convalescent serum (WHO) 25:42
• Immunomodulation and thromboembolic risk (J Clin Med) 28:21
• Long COVID after infection of vaccinated (medRxiv) 30:58
• Letters read on TWiV 840 36:38
• Timestamps by Jolene. Thanks!

每周播報：https://www.microbe.tv/twiv/